Literature DB >> 31656809

Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: "Midsummer Night's Dream" or "Much Ado About Nothing"?

Alessandro Antonelli1,2, Carlotta Palumbo1,2, Alfredo Berruti1,3.   

Abstract

Entities:  

Year:  2019        PMID： 31656809      PMCID： PMC6789321          DOI： 10.21037/atm.2019.07.84

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  16 in total

1.  Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline.

Authors:  Raisa S Pompe; Pierre I Karakiewicz; Zhe Tian; Philipp Mandel; Thomas Steuber; Thorsten Schlomm; Georg Salomon; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  J Urol       Date:  2017-02-16       Impact factor: 7.450

2.  Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.

Authors:  Eleni Efstathiou; John W Davis; Louis Pisters; Weimin Li; Sijin Wen; Ryan P McMullin; Michael Gormley; Deborah Ricci; Mark Titus; Anh Hoang; Amado J Zurita; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Patricia Troncoso; Christopher J Logothetis
Journal:  Eur Urol       Date:  2019-06-06       Impact factor: 20.096

Review 3.  Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.

Authors:  Alfredo Berruti; Vito Amoroso; Fabio Gallo; Valentina Bertaglia; Edda Simoncini; Rebecca Pedersini; Laura Ferrari; Alberto Bottini; Paolo Bruzzi; Maria Pia Sormani
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

4.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Authors:  Ian D Davis; Andrew J Martin; Martin R Stockler; Stephen Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy Parulekar; David W Pook; M Neil Reaume; Shahneen K Sandhu; Alvin Tan; T Hsiang Tan; Alastair Thomson; Emily Tu; Francisco Vera-Badillo; Scott G Williams; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

5.  Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment.

Authors:  Roderick van den Bergh; Giorgio Gandaglia; Derya Tilki; Hendrik Borgmann; Piet Ost; Christian Surcel; Massimo Valerio; Prasanna Sooriakumaran; Laurent Salomon; Alberto Briganti; Markus Graefen; Henk van der Poel; Alexandre de la Taille; Francesco Montorsi; Guillaume Ploussard
Journal:  Eur Urol Focus       Date:  2017-08-08

6.  Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Authors:  Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

7.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

8.  Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

Authors:  Rana R McKay; Huihui Ye; Wanling Xie; Rosina Lis; Carla Calagua; Zhenwei Zhang; Quoc-Dien Trinh; Steven L Chang; Lauren C Harshman; Ashley E Ross; Kenneth J Pienta; Daniel W Lin; William J Ellis; Bruce Montgomery; Peter Chang; Andrew A Wagner; Glenn J Bubley; Adam S Kibel; Mary-Ellen Taplin
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

9.  Androgen deprivation modulates gene expression profile along prostate cancer progression.

Authors:  Marco Volante; Daniele Tota; Jessica Giorcelli; Enrico Bollito; Francesca Napoli; Simona Vatrano; Consuelo Buttigliero; Luca Molinaro; Paolo Gontero; Francesco Porpiglia; Marcello Tucci; Mauro Papotti; Alfredo Berruti; Ida Rapa
Journal:  Hum Pathol       Date:  2016-06-21       Impact factor: 3.466

Review 10.  Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Authors:  Larysa H M Rydzewska; Sarah Burdett; Claire L Vale; Noel W Clarke; Karim Fizazi; Thian Kheoh; Malcolm D Mason; Branko Miladinovic; Nicholas D James; Mahesh K B Parmar; Melissa R Spears; Christopher J Sweeney; Matthew R Sydes; NamPhuong Tran; Jayne F Tierney
Journal:  Eur J Cancer       Date:  2017-08-08       Impact factor: 9.162
View more
  1 in total

1.  The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials.

Authors:  Guobin Tan; Zijun Xuan; Zhiqin Li; Shuitong Huang; Guangming Chen; Yonglu Wu; Xianxi Chen; Zhijin Liang; Aiming Wu
Journal:  Transl Androl Urol       Date:  2020-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.